ACTIVE STUDIES RECRUITING:

• J1I-MC-GZQA (TRANSCEND-T2D-3) – Kidney Disease / Type 2 Diabetes / Insulin

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

ACTIVE STUDIES NON-RECRUITING:

• J1I-MC-GZBU – T2DM/ Kidney Disease/ Overweight and Obesity

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

COMPLETED STUDIES:

  • AstraZeneca – D9183C0001 – DKD – 2023

  • Bayer – 16244(FIDELIO) – CKD – 2020

  • Bayer – 17530 (FIGARO) – DKD – 2021

  • CSL Behring – CSL346_2001 (MANEUVER) – DKD – 2022

  • Eli Lilly and Co. – H9X-MC-GBDX – T2DM / CKD – 2016

  • Ironwood Pharmaceuticals – C1973-203 – T2DM w/ Diabetic Nephropathy – 2019

  • Janssen Research & Development, LLC – 28431754DNE3001 (CREDENCE) – T2DM/Diabetic Nephropathy – 2018

  • Teijin America Inc. – TMX-049DN-201 – DKD – 2019

  • CR845-310301 – CKD/Pruritus

info@PlanItResearch.com